Autonomous AI Agents Discover Aging Interventions from Millions of Molecular Profiles
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.
View abstract on PubMed
Summary
This summary is machine-generated.AI agents analyzed millions of molecular samples to find interventions that modify biological age. ClockBase Agent identified over 500 interventions that significantly reduce aging, transforming longevity research.
Area Of Science
- Biogerontology
- Computational Biology
- Genomics
Background
- Vast molecular datasets exist but are underutilized for aging research.
- Aging clocks can now estimate biological age and predict outcomes from molecular data.
- Systematic analysis of existing data offers a new avenue for discovering longevity interventions.
Purpose Of The Study
- To develop an AI-powered platform (ClockBase Agent) for reanalyzing molecular data to identify age-modifying interventions.
- To autonomously generate hypotheses, evaluate intervention effects on biological age, and produce scientific reports.
- To uncover fundamental patterns in interventions affecting aging across human and mouse models.
Main Methods
- Developed ClockBase Agent, integrating millions of human and mouse methylation and RNA-seq samples with over 40 aging clock predictions.
- Employed specialized AI agents for autonomous hypothesis generation, intervention effect evaluation, literature review, and report production.
- Conducted large-scale reanalysis of 43,602 intervention-control comparisons using multiple aging biomarkers.
Main Results
- Identified thousands of age-modifying effects, including over 500 interventions that significantly reduce biological age (e.g., ouabain, KMO inhibitor, fenofibrate).
- Revealed patterns: more interventions accelerate aging, diseases accelerate biological age, and loss-of-function genetic approaches are superior for deceleration.
- Validated AI-identified interventions by showing convergence on longevity pathways and concordance with lifespan databases.
- Experimentally validated ouabain in aged mice, showing reduced frailty, neuroinflammation, and improved cardiac function.
Conclusions
- ClockBase Agent establishes a new paradigm for autonomous discovery of age-modifying interventions by reanalyzing existing research.
- The platform transforms data extraction for biological insights, advancing human healthspan and longevity.
- AI-driven systematic reanalysis of molecular data is a powerful tool for identifying novel therapeutic strategies for aging.
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.
Related Concept Videos
Aging is a complex biological phenomenon influenced by various processes that affect cellular and systemic functions. Several prominent theories attempt to explain its mechanisms, highlighting cellular limitations, oxidative damage, and hormonal changes as central factors in aging.
Cellular Clock Theory
The cellular clock theory posits that the human lifespan is closely tied to the finite capacity of cells to divide, a phenomenon governed by telomeres, which are protective caps at the ends of...
Several body functions deteriorate with age. The external signs of aging are easily identifiable. For example, the skin becomes dry, less elastic, and thins out, forming wrinkles. The skin of the face begins to appear looser due to a decrease in the levels of elastic and collagen fibers in the connective tissue. Additionally, melanin production in the hair follicle decreases with age, resulting in gray hair. Moreover, the senses of sight and hearing decline, so glasses and hearing aids may...
Cancer cells accumulate genetic changes at an abnormally rapid rate due to the defects in the DNA repair mechanisms. From an evolutionary perspective, such genetic instability is advantageous for cancer development. Mutant cell lines accumulate a series of beneficial mutations that contribute to their progression into cancer.
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
Age-related pharmacokinetic changes are extensively documented, but understanding age-related pharmacodynamic alterations is relatively limited. This knowledge gap can be partly attributed to the complexity of developing appropriate measures of drug responses compared to bioanalytical methods for determining drug concentrations.Most information regarding age-related differences in human pharmacodynamics originates from cross-sectional studies. However, these studies assume that observed mean...
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...